These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 1879047)

  • 41. Doxorubicin clearance in the obese.
    Rodvold KA; Rushing DA; Tewksbury DA
    J Clin Oncol; 1988 Aug; 6(8):1321-7. PubMed ID: 3411343
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Doxorubicin pharmacokinetics following a single-dose infusion to sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; Charles BG
    Aust Vet J; 2004 Dec; 82(12):769-72. PubMed ID: 15648940
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.
    Greene RF; Collins JM; Jenkins JF; Speyer JL; Myers CE
    Cancer Res; 1983 Jul; 43(7):3417-21. PubMed ID: 6850648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.
    Bressolle F; Jacquet JM; Galtier M; Jourdan J; Donadio D; Rossi JF
    Cancer Chemother Pharmacol; 1992; 30(3):215-8. PubMed ID: 1628370
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.
    Morgan RJ; Doroshow JH; Venkataraman K; Chang K; Raschko J; Somlo G; Leong L; Tetef M; Shibata S; Hamasaki V; Margolin K; Forman S; Akman S; Coluzzi P; Ahn C; Weiss L; Gadgil U; Harrison J
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2337-45. PubMed ID: 9815632
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients.
    Embree L; Gelmon KA; Lohr A; Mayer LD; Coldman AJ; Cullis PR; Palaitis W; Pilkiewicz F; Hudon NJ; Heggie JR
    J Pharm Sci; 1993 Jun; 82(6):627-34. PubMed ID: 8392545
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
    Sparano JA; Speyer J; Gradishar WJ; Liebes L; Sridhara R; Mendoza S; Fry D; Egorin MJ
    J Clin Oncol; 1999 Mar; 17(3):880-6. PubMed ID: 10071279
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and pharmacokinetic study of 96-h infusions of doxorubicin in advanced cancer patients.
    Bugat R; Robert J; Herrera A; Pinel MC; Huet S; Chevreau C; Boussin G; Roquain J; Carton M
    Eur J Cancer Clin Oncol; 1989 Mar; 25(3):505-11. PubMed ID: 2703005
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alteration in doxorubicin and doxorubicinol plasma concentrations with repeated courses to patients.
    Morris RG; Reece PA; Dale BM; Green RM; Kotasek D; Saccoia NC; Sage RE
    Ther Drug Monit; 1989; 11(4):380-3. PubMed ID: 2741185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetic properties of doxorubicin encapsulated in glutaraldehyde-treated canine erythrocytes.
    Tonetti M; Astroff AB; Satterfield W; De Flora A; Benatti U; DeLoach JR
    Am J Vet Res; 1991 Oct; 52(10):1630-5. PubMed ID: 1767983
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparative study on the antitumor effect, cardiotoxicity and nephrotoxicity of doxorubicin given as a bolus, continuous infusion or entrapped in liposomes in the Lou/M Wsl rat.
    Storm G; van Hoesel QG; de Groot G; Kop W; Steerenberg PA; Hillen FC
    Cancer Chemother Pharmacol; 1989; 24(6):341-8. PubMed ID: 2791187
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio.
    Pippa LF; Oliveira ML; Rocha A; de Andrade JM; Lanchote VL
    J Pharm Biomed Anal; 2020 Jun; 185():113231. PubMed ID: 32163849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
    Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
    Wilson WH; Berg SL; Bryant G; Wittes RE; Bates S; Fojo A; Steinberg SM; Goldspiel BR; Herdt J; O'Shaughnessy J
    J Clin Oncol; 1994 Aug; 12(8):1621-9. PubMed ID: 7913721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
    Gabra H; Cameron DA; Lee LE; Mackay J; Leonard RC
    Br J Cancer; 1996 Dec; 74(12):2008-12. PubMed ID: 8980405
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.
    Jacquet JM; Bressolle F; Galtier M; Bourrier M; Donadio D; Jourdan J; Rossi JF
    Cancer Chemother Pharmacol; 1990; 27(3):219-25. PubMed ID: 2265458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; McGeary RP; Charles BG
    Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors.
    Casper ES; Gaynor JJ; Hajdu SI; Magill GB; Tan C; Friedrich C; Brennan MF
    Cancer; 1991 Sep; 68(6):1221-9. PubMed ID: 1873773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.